Technology is rapidly influencing the way we prevent, treat and manage diseases.
With the rise in digital health solutions, there is a growing need to understand and identify where digital tools can add value, and build a business case that can drive both patient and business outcomes.
That’s why we are here.
By embracing digital measures, pharma can accelerate drug development, improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Digital measures have the potential to revolutionise drug development. However, pharma has been slow to fully utilise these measures due to their high costs and lack of standardised applications across therapeutic areas.
This report presents an expert-led analysis of the state of digital measures in drug development. More specifically, the report delves into:
Download the report to learn what our HealthXL community experts believe is in store for the future of digital measures in drug development and how best to prepare for it.
We help clients across the world champion digital health innovation
